Cargando…
BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes
BACKGROUND: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease with a high risk of induction failure and poor outcomes, with relapse due to drug resistance. Recent studies show that bromodomains and extra-terminal (BET) protein inhibitors are promising anti-cancer agents. ARV-825,...
Autores principales: | Wu, Shuiyan, Jiang, You, Hong, Yi, Chu, Xinran, Zhang, Zimu, Tao, Yanfang, Fan, Ziwei, Bai, Zhenjiang, Li, Xiaolu, Chen, Yanling, Li, Zhiheng, Ding, Xin, Lv, Haitao, Du, Xiaoli, Lim, Su Lin, Zhang, Yongping, Huang, Saihu, Lu, Jun, Pan, Jian, Hu, Shaoyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061034/ https://www.ncbi.nlm.nih.gov/pubmed/33888130 http://dx.doi.org/10.1186/s12935-021-01908-w |
Ejemplares similares
-
PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc
por: Li, Zhiheng, et al.
Publicado: (2020) -
A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells
por: Zhang, Kunlong, et al.
Publicado: (2022) -
BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes
por: Ma, Li, et al.
Publicado: (2022) -
ARV-825 Demonstrates Antitumor Activity in Gastric Cancer via MYC-Targets and G2M-Checkpoint Signaling Pathways
por: Liao, Xinmei, et al.
Publicado: (2021) -
ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma
por: He, Ling, et al.
Publicado: (2020)